P536: Characterizing a cohort of Parkinson's disease patients and controls in a Peripheral Biomarker Development Study

Despite the success of biomarker research in other neurodegenerative diseases, Parkinson’s disease (PD) has remained challenging for biomarker development. As a result, patients with early signs of PD may experience delays in diagnosis and treatment. Researchers at the HudsonAlpha Institute for Biotechnology in Huntsville, AL, have previously identified small RNA signatures in amyotrophic lateral sclerosis (ALS) patients that hold potential for earlier diagnosis and monitoring of disease progression.